(Q54106224)

English

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

0 references

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. (English)

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Claes Göran Tropé

1

object named as

C Tropé

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

author name string

T Hogberg

2

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

J Kaern

3

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

K Bertelsen

4

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

E Bjorkholm

5

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

K Boman

6

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

A Himmelmann

7

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

G Horvath

8

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

A Jacobsen

9

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

T Kuoppola

10

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

J Vartianen

11

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

B Lund

12

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

M Onsrud

13

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

U Puistola

14

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

T Salmi

15

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

M Scheistroen

16

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

R Sandvei

17

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

E Simonsen

18

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

B Sorbe

19

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

B Tholander

20

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

R Westberg

21

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

publication date

1 December 1998

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

Annals of Oncology

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

9

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

12

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

1301-1307

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival experience of female patients with genital cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008400324892

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008400324892

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/9932160

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54106224&oldid=1561397465"